Eli Lilly has launched its much-awaited weight loss medicine, Mounjaro (tirzepatide), in India. Mounjaro is a weekly injectable medicine intended to treat weight and enhance blood sugar regulation in people with obesity or other weight-related conditions.
How Mounjaro Works
Mounjaro acts on two major hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By activating these two receptors, the drug achieves blood sugar control as well as curbs hunger, resulting in notable weight loss. This two-receptor action makes Mounjaro different from other weight loss medications that generally act on a single receptor.
Clinical Trial Results
Clinical trials have shown that Mounjaro can result in substantial weight loss. In a 72-week trial, users of the drug had an average body weight loss of as much as 20%. The trials also showed improvements in overall metabolic health, such as improved blood sugar control and lower cardiovascular risks.
Pricing and Availability
Mounjaro has been launched in India at a cost of ₹3,500 for the 2.5 mg strength and ₹4,375 for the 5 mg strength. The drug is aimed at people with a body mass index (BMI) of more than 30 or a BMI of more than 27 with weight-related medical conditions like type 2 diabetes, high blood pressure, or high cholesterol.
Side Effects and Safety
Although Mounjaro has presented encouraging results, it is not free of side effects. Frequent side effects are nausea, vomiting, diarrhea, and discomfort in the stomach. More dangerous but less frequent complications are thyroid tumors, pancreatitis, and severe allergic attacks. Patients must consult their physician prior to using the treatment.
Impact on the Indian Market
The launch of Mounjaro is a huge milestone in tackling the escalating obesity and diabetes epidemic in India. As lifestyle-related diseases are on the upsurge, Mounjaro provides a new answer for those who are battling weight management and metabolic issues. The experts opine that the release of the drug can take some pressure off the healthcare system and enhance the quality of life among patients overall.
Eli Lilly’s move into the Indian weight loss space with Mounjaro indicates the growing demand for efficient treatments for obesity. The drug’s dual mechanism and encouraging trial data make it a potentially game-altering choice for weight control in India.
